CYP1B1-IN-9

CYP1B1-IN-9 (Compound B20) (15-45 min) exhibits the IC₅₀ values of >100 (CYP1A1) and >80 (CYP1A2), and the inhibition rates of CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are 15.7%, 2.21%, 7.73%, 0.0% and 0.940%, respectively^[1].
CYP1B1-IN-9 (20, 40 μM, 48 h) exhibits low cytotoxicity (IC₅₀ HUVEC > 40 μM; IC₅₀ BEAS 2B > 20 μM) and sensitivity in A549/T cells with an IC₅₀ of 7.5 μM^[1].
CYP1B1-IN-9 (2.5 μM, 48 h) has strong synergistic effects with Paclitaxel (0.025 μM, CI = 0.08), confirming the ability to reverse multidrug resistance through CYP1B1 inhibition^[1].
CYP1B1-IN-9 (2.5-10 μM, 24 h) concentration-dependently suppressed A549/T cell migration^[1].
CYP1B1-IN-9 (5-60 min, 0.5 mg/mL) has superior metabolic stability with half-lives (T_1/2) of exceeding 60 min and intrinsic clearance rates (CL_int) of 1.1 mL/min/kg in vitro liver microsomal studies^[1].
CYP1B1-IN-9 (5-120 min, 100 μM) has human plasma stability with T_1/2 values surpassing 2 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.